Janesville-based SHINE Technologies, a manufacturer of medical isotopes, will begin providing one of its flagship products to Sydney, Australia-based Radiopharm Theranostics through a new clinical supply agreement. SHINE will supply Radiopharm with the isotope Lutetium-177.
SHINE first began producing Lutetium-177, also called Lu-177, in April 2021. The company said it saw strong demand for Lu-177 from clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.
Lu-177 will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.